Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy? - HKNOS
Skip to content
HKNOS
The Hong Kong Neuro-Oncology Society
Home
Members/Healthcare professionals
objectives / council members / memberships / contact us
Education Centre
EN
© 2025 The hong kong neuro-oncology society. all rights reserved.
HKNOS
The Hong Kong Neuro-Oncology Society
DONATIONS
EN

Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy?

文章導覽

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase
A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location

Recent Posts

  • [HKNOS Public Events] 【腦腫瘤關注月】甚麼是腦膜瘤？｜鄒淑韻醫生
  • [HKNOS Sponsorship] 20th Annual Meeting of the Asian Society for Neuro-Oncology (ASNO 2025)
  • [Events outside HKNOS] The 18th Annual Meeting of the Korean Society of Medical Oncology & 2025 International Conference
  • HKNOS Annual Scientific Meeting 2024
  • Events outside HKNOS: HSBC-Brain Tumors 2025 18-19 January 2025

Categories

  • Event
  • General Public
  • 未分類
The Hong Kong Neuro-Oncology Society
香港神經腫瘤學會